(Q44438556)

English

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

scientific article published on May 15, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 (English)

reason for preferred rank

most precise value

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

chemoradiotherapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

13

object named as

Southwest Oncology Group

1 reference

Europe PubMed Central

3 December 2017

David R Gandara

1

object named as

David R Gandara

1 reference

Europe PubMed Central

3 December 2017

Laurie E. Gaspar

5

object named as

Laurie E Gaspar

1 reference

Europe PubMed Central

3 December 2017

author name string

Kari Chansky

2

1 reference

Europe PubMed Central

3 December 2017

Howard Burris

7

1 reference

Europe PubMed Central

3 December 2017

Paul Gumerlock

8

1 reference

Europe PubMed Central

3 December 2017

John Crowley

11

1 reference

Europe PubMed Central

3 December 2017

Robert Livingston

12

1 reference

Europe PubMed Central

3 December 2017

Kathy S. Albain

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

Bryan R. Leigh

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

Primo N. Lara

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

J. Philip Kuebler

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

James D. Bearden

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

Southwest Oncology Group

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743155

1 January 2024

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

3 December 2017

15 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12743155

1 January 2024

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.04.197

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

3 December 2017

21

1 reference

Europe PubMed Central

3 December 2017

10

1 reference

Europe PubMed Central

3 December 2017

2004-2010

1 reference

Europe PubMed Central

3 December 2017

Multimodality therapy in stage III non-small cell lung cancer

1

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

2

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

3

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

5

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

6

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

8

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Promising new agents in the treatment of non-small cell lung cancer

9

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel

11

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

12

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

13

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

14

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Nonparametric Estimation from Incomplete Observations

15

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

16

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

18

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial

19

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

21

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

25

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

26

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

27

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial

32

1 reference

10.1200/JCO.2003.04.197

https://api.crossref.org/works/10.1200/JCO.2003.04.197

1 January 2024

Identifiers

10.1200/JCO.2003.04.197

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44438556&oldid=2042581673"